Assessment of Antimicrobial Utilization among Cancer Patients with Febrile Neutropenia at the Lebanese Hospitals

Author:

Cherri Sarah1,Malaeb Diana12,Shouman Lamis1,Fahs Iqbal1,Hallit Rabih345,Hallit Souheil367,Malaeb Bassem8,Salameh Pascale9101112

Affiliation:

1. School of Pharmacy, Lebanese International University, Mouseitbah, Beirut, Lebanon

2. College of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates.

3. School of Medicine and Medical Sciences, Holy Spirit University of Kaslik, Jounieh, Lebanon

4. Department of Infectious Disease, Bellevue Medical Center, Mansourieh, Lebanon

5. Department of Infectious Disease, Notre Dame des Secours, University Hospital Center, Byblos, Lebanon

6. Psychology Department, College of Humanities, Effat University, Jeddah, 21478, Saudi Arabia.

7. Research Department, Psychiatric Hospital of the Cross, Jal Eddib, Lebanon

8. Dr. Sulaiman Al-Habib Medical Group, Dubai, United Arab Emirates

9. INSPECT-LB: Institut National de Santé Publique, Épidémiologie Clinique et Toxicologie, Beirut, Lebanon

10. School of Medicine, Lebanese American University, Byblos, Lebanon

11. Department of Primary Care and Population Health, University of Nicosia Medical School, Nicosia, Cyprus

12. Faculty of Pharmacy, Lebanese University, Hadat, Lebanon

Abstract

Background: Febrile neutropenia is a prevalent oncologic complication. Initiating rapid treatment with empirical antimicrobials in febrile neutropenia patients reduces mortality due to infections. Objectives: The study aims to evaluate antimicrobial utilization among FN patients in Lebanon in terms of drug choice, dose, and duration of the treatment. This is a retrospective, multicenter, observational study conducted at three different Lebanese university hospitals (in which the Infectious Diseases Society of America (IDSA) guidelines are adopted), between February 2014 and May 2017. Setting: This is a retrospective, multicenter, observational study was conducted at three different Lebanese university hospitals (in which the Infectious Diseases Society of America (IDSA) guidelines are adopted), between February 2014 and May 2017. Methods: Adult cancer patients aged 18 years and older with febrile neutropenia were included in the study. Using the IDSA guidelines as a reference, patients were assessed whether they received the antimicrobial regimen inconsistent with the IDSA reference or not. Statistical analysis was performed using the Statistical Package for the Social Science software (SPSS version 22.0). The adherence to guidelines for the indication and doses of antibiotics and anti-fungal in patients with febrile neutropenia. Results: A total of 124 patients with a mean age of 54.43 ± 17.86 years were enrolled in the study. Leukemia (29.7%) was the most prevalent cancer and the most common infection was sepsis (20.2%). Combination antibiotic lactams are the most prescribed antibiotics (86.8%). Only 94 (86.23%) patients were given the antibiotic therapy appropriate for choice, dose, and duration. Empirical antifungal therapy was initiated in 63.7% of the patients and fluconazole was the most used antifungal (36.3%). In contrast to antibiotics, the majority of antifungal choices were not selected according to the recommendations and they were considered inappropriate for doses and the required treatment duration as proposed by (IDSA). Fifty-eight percent of patients received antivirals, even though it is not recommended as empirical treatment. Conclusion: In conclusion, this study reveals a non-consistent antimicrobial utilization practice at the involved sites concerning FN treatment. Inappropriateness was encountered in drug selection, dose, and duration of treatment with antifungals and antivirals.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Pharmacology,Toxicology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3